Life sciences and health care horizons - March 2018

Published date04 April 2018
Law FirmHogan Lovells
AuthorJane Summerfield,Yarmela Pavlovic,Alice Valder Curran,Elisabethann Wright,Riccardo Fruscalzo,Susan Lee,Natalia Gulyaeva,Heidi Forster Gertner,Stuart Langbein,Robert Church,David Fox,Randy Prebula,Melissa Bianchi,Matthew Felwick,Virginia Gibson,Hein Van den Bos,Lu Zhou,Leigh Oliver,Marcy Wilder,Dr. Matthias Schweiger,Vaughn Harrison,Michael Druckman,Sammy Li,David Horowitz,Fabrizio Lolliri,Jason Hadges,Lynn Mehler,H. Todd Miller,John Salmon,Dr. Frederick Ch'en,Dr. Jörg Schickert,Robert Darwin,Arne Thiermann, LL.M. (LSE),Xin Tao,Asher Rubin,Stephen Peepels,Massimiliano Masnada,Ina Brock,Adam Golden,Ernesto Algaba Reyes,Mitchell Lazris,Anthony Fuller,Dr. Marion Palmer
Subject MatterAcquisitions,Mergers,Data Breach,Emerging Markets,Life Sciences,Transfer Pricing,OTC,EU,Innovation,Cybersecurity,Private Equity,Biotechnology,Medical Reimbursement,Prescription Drugs,Biosimilars,Cyber Attacks,Digital Health,Generic Drugs,Supply Chain,Biologics,3D Printing,Drug Pricing,Regulatory Oversight,Yates Memorandum,UK Brexit,General Data Protection Regulation (GDPR),Pharmaceutical Industry,Artificial Intelligence,Distributed Ledger Technology (DLT),Blockchain

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT